Approved, investigational, compounded, or “research use only”?
Four labels that sound related online but answer four different questions.
FDA approval belongs to a specific drug product and use. A clinical trial studies a defined intervention. Compounding is a separate legal framework. “Research use only” is not a shield when the surrounding marketing shows intended human use.
FDA-approved
FDA has reviewed a specific product for specified conditions of use. The formulation, manufacturer, route, strength, labeling, and indication matter. Approval of one product does not automatically approve every product sold under the same ingredient name.
Investigational
A substance can be in a legitimate clinical trial without being FDA-approved. Trial phase, completion, a press release, and a positive endpoint are milestones — not interchangeable with approval.
Compounded
Compounded drugs are not FDA-approved. Federal law provides limited pathways and conditions under sections 503A and 503B, including restrictions on which bulk drug substances may be used. Whether a substance appears in a discussion category, receives an advisory vote, or is placed on a final list are different regulatory events.
“Research use only”
FDA evaluates intended use from the full context, not one disclaimer. Warning letters have treated peptide products labeled “Research Use Only” as unapproved drugs when the surrounding claims and sales context showed intended human use.